Home / Stocks / FENC

Fennec Pharmaceuticals (FENC, Biotechnology) Stock Valuation & Fair Value No P/E valuation

Fennec Pharmaceuticals (FENC, Biotechnology) trades at a blended P/E of 95.5, trading without a historical P/E to compare against, with a forward growth estimate above 100% and a PEG of 0.42. Analysts' one-year estimates have been hit 29% of the time.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-09-21
Blended P/E
95.5
Normal P/E
—
PEG
0.42
Fwd growth
>100%
Div yield
0.0%
RSI (14)
46.4
Neutral

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-08-07, because this company has no P/E to compare against its own history.

Blended P/E and rating by weekBlended P/E moved from 4,547.8 to 95.5 between 2026-08-07 and 2026-09-21, with 1 rating change over 16 recorded weeks.2026-08-07: P/E 4,547.8, No P/E valuation (recalculated)2026-08-10: P/E 2,893.8, No P/E valuation2026-08-14: P/E 2,893.8, No P/E valuation (recalculated)2026-08-17: P/E 237.4, No P/E valuation2026-08-21: P/E 237.4, No P/E valuation (recalculated)2026-08-24: P/E 182.9, No P/E valuation2026-08-27: P/E 182.9, No P/E valuation (recalculated)2026-08-28: P/E 182.9, No P/E valuation (recalculated)2026-08-30: P/E 182.9, No P/E valuation (recalculated)2026-08-31: P/E 146.1, No P/E valuation2026-09-05: P/E 146.1, No P/E valuation (recalculated)2026-09-07: P/E 128.2, No P/E valuation2026-09-12: P/E 128.2, No P/E valuation (recalculated)2026-09-14: P/E 110.9, No P/E valuation2026-09-19: P/E 110.9, No P/E valuation (recalculated)2026-09-21: P/E 95.5, No P/E valuation2,000.04,000.0Aug 7Aug 18Aug 29Sep 10Sep 21
Attractively valuedNo P/E valuationAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-07P/E 4,547.8not availableNo P/E valuation
2026-09-21P/E 95.5not availableNo P/E valuation ← now

Frequently asked questions

Is Fennec Pharmaceuticals stock overvalued?

At a blended P/E of 95.5, Fennec Pharmaceuticals has no historical normal P/E on record to compare that against, with a PEG of 0.42 on forward growth above 100%. tickerseer therefore publishes no valuation rating for it.

What is Fennec Pharmaceuticals's fair value and PEG?

Fennec Pharmaceuticals trades at a blended P/E of 95.5, a PEG of 0.42, and a forward growth estimate above 100%.

Has tickerseer's rating of Fennec Pharmaceuticals changed?

tickerseer has published no valuation rating since 2026-08-07, because this company has no P/E to compare against its own history.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track FENC free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.